Introduction
Most physicians and gastroenterologists acknowledge that the medical treatment for irritable bowel syndrome (IBS) is empirical, not necessarily based on pathophysiological findings and substantially lacking in efficacy. Thus, increasingly disillusioned, patients are left with persistent and significant symptoms which may interfere with their ability to cope with certain stressful life events as reflected by absence from work, marital disharmony and increased use of health resources.
The definition of IBS has recently been placed on firmer grounds with the symptom based Rome criteria. However, it seems clear that patients with IBS have many symptoms that these criteria do not cover. These include bloating, abdominal distension, food intolerances that do not appear to have a rational biochemical explanation, chemical sensitivities, reduced tolerance of alcohol, flatulence and bulimia. There are also extraintestinal symptoms such as profound tiredness, depression, anxiety, lack of self confidence, arthralgia, myalgia, pre-menstrual and perimenstrual tension, for example. Lack of interest in these symptoms may be due to our inability to treat them effectively. However, this leaves many patients with the perception of a lack of coordinated attention to their diverse symptoms and many seek help from alternative medicine.
It is becoming increasingly clear that the above IBS associated symptoms are similar to the symptom complexes of chronic fatigue syndrome, and multiple chemical sensitivities. A common theme with these 'unexplained symptom complexes' is that the disability seems to be out of proportion to physical findings [1, 2] . The place of these symptom based disorders within the nosology of clinical medicine is uncertain.
From the non-traditionalist gastroenterological point of view there have been evolving attempts to account for the 'unexplained clinical symptoms' associated with IBS. High carbohydrate intake in some of these patients prompted diagnostic labels such as germ-carbohydrate fermentation and intestinal carbohydrate dyspepsia [3] in the early 20th century, while later attempts include descriptions of the candidiasis hypersensitivity syndrome [4] , gut fermentation syndrome [5] , fungal type dysbiosis [6] [7] [8] [9] and abnormal gut fermentation [10] [11] [12] . All these have in common a general tendency to describe IBS in terms of normal, or abnormal intestinal microbiological flora resulting in gut fermentation problems, yeast sensitivity and dysbiosis. Others have observed that yeast overgrowth occurs in certain situations where there is abundance of carbohydrates [13] [14] [15] and it is suggested that the symptoms in patients with gut dysbiosis are worsened by exposure to yeast and mould containing foods [7] . Much of this work is admittedly controversial. The idea of the Candida syndrome or Candida hypersensitivity, i.e., that intestinal colonization with Candida albicans is one cause of IBS symptoms or the 'unexplained symptom complex' of IBS, has received widespread publicity in the popular press. Patients are thus increasingly asking their health providers for information, clarification and treatment of yeast related issues. The possible role of Candida and yeast in non-immune compromised individuals is disputed and is the subject of this review.
Biology of Candida albicans
The three major groups of fungi are moulds, yeasts and mushrooms. Candida are unicellular yeasts, somewhat larger than bacteria, that divide mostly asexually, can switch between a yeast-and a pseudohyphal or hyphal form and, like other yeasts, flourish in habitats where there is an abundance of sugar. Candida are normal human commensals, particularly in the mouth, skin, vagina and intestine. Candida can be cultured from faeces in up to 80% of healthy adults [16] [17] [18] . Candida numbers increase significantly following antibacterial therapy [19, 20] , but the numbers seem to be unaffected by a refined carbohydrate diet [21] . It seems likely that intestinal Candida numbers are regulated in a similar way as intestinal bacteria [22, 23] .
Candida albicans is the most common cause of candidiasis in humans, but other species of Candida such as C. tropicalis, C. parapsilosis, C. krusei and C. glabrata may also be responsible. The pathogenesis of disease associated with Candida in humans is driven by host factors. Candida does not seem to produce specific mycotoxins [24] although some produce gliotoxin which may impair neutrophil function [25] .
However, it is a polyantigenic organism containing up to 178 different antigens [26] [27] [28] , which might explain the number of cross-reactions to yeasts (Malassezia, breasd/brewer's yeast) and moulds [28, 29] and even human tissue [30] . It was shown recently that there is a potential cross reactivity with gluten because of several amino acid sequences that are highly homologous to alpha-gliadin and gamma-gliadin. Such a mechanism might lead to wheat intolerance with its accompanying symptoms and even trigger coeliac disease in genetically susceptible people [31] . Furthermore, a placebo controlled crossover study revealed that dietary yeast may affect the activity of Crohn's disease [32] Candida produces alcohol [10] and contains glycoproteins which have the potential to stimulate mast cells to release histamine and apparently prostaglandin (PGE2), inflammatory substances which could cause IBS-like symptoms [33] [34] [35] . Other circumstantial evidence supports the theory of yeasts as trigger for the IBS: secretory immunoglobulin A (SIgA) is front line in the defence of mucous membranes, especially in the intestine where it is active against infectious agents and certain antigens [36] . At least three different Candida species are able to produce proteases which can degrade IgA1, IgA2 and SIgA [37] . This protease activity can induce polyclonal B-cell response and inflammation. An infection of the intestinal mucosa with Candida might lead to an inactivation of SIgA and inflammation within subgroups of patients with IBS symptoms.
Candida is sensitive to a number of antifungal agents, such as nystatin, which is not absorbed from the gastrointestinal tract after oral administration. It destroys Candida by binding to sterols in the cell membrane, and thereby increasing permeability with loss of cellular contents.
Epidemiology of intestinal Candida
There are no satisfactory studies addressing intestinal colonization of Candida in IBS patients that support, or refute a causative effect. A recent review, however, concluded that there was a strong association between improvement of diarrhoeal symptoms in patients recently treated with antibacterials, who had a significant overgrowth of Candida in their stools and treatment with antifungal agents [38] . Renfro et al. [39] investigated 100 consecutive patients (using symptom based questionnaires) with chronic fatigue and compared those who believed that their 'unexplained symptom complex' and chronic fatigue was due to yeast to those who did not hold this belief. There were no specific features that supported the preconceived belief that Candida caused the fatigue. The authors attributed most of the symptoms to psychiatric factors.
A study from France suggested that the presence in the intestinal tract of yeasts (Candida albicans, Geotrichum candidum) caused IBS symptoms in atopic individuals [40] . However, antibodies to Candida are frequently seen in atopic and allergic individuals without IBS [41, 28] .
While some of these studies question the validity of a causative relationship between intestinal Candida and IBS, a lack of association might be due to methodological problems.
Diagnostic tests
Laboratory investigations into the possible role of yeast in polysymptomatic patients, especially those with IBS and chronic fatigue, have been problematic because there is no accepted 'gold standard' for distinguishing between a yeast sensitivity condition and a yeast overgrowth in the gut. Candida, infection is well documented in vaginal and oral-oesophageal candidiasis. Biopsies or smears examined by microscopy, or cultures on yeast-friendly media are routinely used are to identify the causative organism. However, establishing that yeast is pathogenically involved is more problematic where the intestine is concerned.
Stool tests for yeast are commercially available, but they are used with limited and variable success. While it might be useful to examine stool or rectal smears by microscopy and/or culture for yeasts, these investigations usually do not distinguish between commensal yeasts and potentially pathogenic Candida [38, 42] .
Direct sampling of luminal contents of the small and/or large bowel in order to study yeast overgrowth has not been widely used because of invasive nature of sample collection [7] and uncertainties regarding interpretation. Furthermore, Middleton et al. [43] did not reveal an association or a correlation between a group with IBS benefiting from antifungal treatment and microbiological finding of yeasts in stools. Evidence for yeast as a causative factor for symptoms has rather been sought from indirect measurements that look for evidence of yeast metabolites in blood, breath or urine [5, 6, 10, 12, [44] [45] [46] , or that explore yeast allergy/sensitivity [12, 44, [47] [48] [49] [50] [51] [52] [53] .
Analyses of studies that describe tests for Candida show that the analytical methods are sound, but in many cases the sensitivity and specificity of the methods has not been assessed extensively and the usefulness of some of the tests awaits confirmation. Some tests explore the possibility that intestinal yeasts metabolize an oral glucose load by measuring blood ethanol 1 h after ingestion of a test solution [9, 45, 46] . These tests have been further developed to include analyses of a range of other alcohols that bacteria, rather than yeast, can produce [6, 10] . The test attempts, and has the potential, to identify patients where yeast overgrowth is of sufficient magnitude to produce measurable metabolites in circulation and distinguish this from bacterial overgrowth, or bacterial dysbiosis [6] [7] [8] 11] . Unfortunately, the glucose challenge test is not specific and cannot show that abnormal findings are due to Candida albicans or, for that matter, any other yeast.
A large number of allergy tests exist with extracts of Candida albicans used for prick or intradermal skin testing as well as for in-vitro tests (RAST, ELISA). But the interpretation of test results is difficult, due to standardization problems with the extracts (different antigen quantity and quality from different Candida strains, grown on different growth media and antigens selected from different parts of the yeast), cross-reactivity between other yeasts and moulds and last not least different antibody responses (IgE, IgA, IgG, IgM). Not suprisingly, many of these test do not distinguish patients from normal controls [48] [49] [50] [51] . Measurement of a combination of antigen, antibody and immune complexes in the serum may be most valuable in the diagnosis of fungus-related disease [52] [53] [54] . Most promising are new recombinant fungus allergens, which are clearly superior to fungal extracts for diagnostic purposes as deduced from the significant correlations obtained between skin test outcome and serology [29] .
Another attempt to find patients belonging to a subgroup with IBS and polysymptomatic symptoms caused by Candida is by questionnaires. Unfortunately, only very few of those have been validated. In an open, retrospective study, a widely used 70-item questionnaire [4] has been filled out by 380 patients who were evaluated after a 3-week treatment with the broad spectrum antifungal nystatin. The questionnaires from the responders were compared to those from the nonresponders in a gradual statistical discrimination analysis. The statisticians concluded that by using only seven questions (Fungus-Related-Disease-Questionnaire-7, FRDQ-7, see Appendix 1) of the original 70-item questionnaire, one could predict a positive response in 95% to the treatment used in this study [55] .
Treatment of 'Candida syndrome'
Proposed treatment of 'intestinal candidiasis' involves dietary management and specific antifungal treatment. The dietary change usually involves a low carbohydrate diet. The rationale for this approach is that fungi thrive on carbohydrates. However, most complex carbohydrates are broken down into monosaccharides, which are absorbed in the proximal jejunum, although a small proportion of ingested sugar may survive as lactulose in lactase-deficient subjects.
There are several published Candida treatment trials. A group of volunteers was studied (mouth wash and stool yeast quantification and differentiation) before, during and after a high-sugar diet [21] . Refined carbohydrates had no significant effect on Candida numbers or subspecies in the mouth or intestine.
In a small number of reported patients with 'Candida induced diarrhoea' (defined as the development of diarrhoea after a course of an antibiotic and which is associated with high faecal Candida levels) there appears to have been a 100% response following antifungal treatment [38] . In an open study of 25 patients (six of whom had received antibiotics) with prolonged diarrhoea (average 16 months) 18 (72%) responded within a few days of nystatin treatment [56] . A response rate of over 90% of patients with flatulence treated with oral antifungal agents is difficult to interpret as there was no control group [57] . However, in a double-blind trial in women with recurrent vaginal candidiasis and the 'candida hypersensitivity syndrome' (multiple unexplained symptom complex, including gastrointestinal) oral and/or vaginal nystatin relieved the vaginal, but not the systemic symptoms [58] . Unfortunately, Dismukes and co-workers chose a crossover protocol, inappropriate for studying an antimicrobial agent [54] .
A recent study again raises the possibility of antifungal treatment in selected polysymptomatic persons [55] . Patients from all parts of Norway were recruited (via one press advertisement) to take part in the study. Of 1620 patients who believed that their 'unexplained symptom complex' was due to yeast and who contacted the investigator, 954 were excluded according to pre-determined criteria and, of the remaining 666, 120 recorded high scores on the questionnaire FRDQ-7, indicating a probable 'fungus related complex'. These were randomly assigned to receive either nystatin or placebo in a double-blind, randomized placebo controlled, multi-centre trial with block design and diet as the block factor. Patients were asked to choose between continuation of their regular diet or a modified diet that was free from sugar, yeast and fungus antigens (see Appendix 2) .
The effect of treatment was monitored by a 45-item symptom questionnaire. The difference between the nystatin groups (nystatin, nystatin + diet) and the placebo groups (placebo, placebo + diet) was highly significant (P , 0.003), as was the difference between the groups following their regular diet or a diet free from sugar, yeast and fungus antigens. Unfortunately the diets have not been administered in a double-blind way.
The best improvement was seen in symptoms attributed to the central nervous system (fatigue, feeling of being drained, frequent mood swings, attacks of anxiety or crying, feeling spacey or unreal, poor memory, dizziness, insomnia, inability to make decisions and depression). Although most of the 120 volunteers had IBS-like symtoms, only nine had actually been diagnosed with IBS. This small subgroup showed a significant improvement of symptoms (35%) after taking nystatin, while the IBS-patients in the placebo groups improved with only 9%.
Conclusions
Although the notion that intestinal Candida has an adverse effect on patients' health has been around for a long time, there has been little progress in the development of techniques that can diagnose the condition with any degree of sensitivity or specificity. The main developments of diagnostic methods involve indirect evidence for the presence of yeast. But even if the involvement of yeasts in the aetiology of IBS still remains unclear, there is increasing evidence for yeasts being able to cause IBS-symptoms in sensitized patients via Candida products, antigens and cross-antigens. Nevertheless, the main criticism of the idea of a fungus related syndrome in non-immune compromised or postantibiotic treated patients has been the lack of controlled treatment trials. In two recent controlled trials of antifungal treatment, one showed no significant effects on systemic symptoms, while the other reported a significant improvement of patients selected by a new questionnaire. This questionnaire (FRDQ-7) may be an effective tool to identify a subgroup with IBS related to yeasts and moulds. Additional improvement by a modified diet free from sugar, yeast and fungus antigens might even justify antifungal treatment.
